EGFR and non-small cell lung carcinoma: The outcomes from treatment with erlotinib and gefitinib in this study of 752 patients with advanced EGFR-mutant nonsquamous NSCLC, treated between 2010 and 2020 in New Zealand, corresponded with those reported in randomized controlled trials and in other large-scale health care system–wide retrospective cohort analyses.